Start with the diagnosis, not the destination
Acute leukemia is not one disease. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) differ in biology, risk grouping and treatment, and the World Health Organization classification separates subtypes that carry different prognoses and different therapies. A treatment plan built on an uncertain subtype is not a plan worth travelling for.
So the first question is not "which hospital in China?" but "what exactly has been diagnosed, and on what evidence?" Ask the current team for the pathology report, the immunophenotyping (flow cytometry) results, cytogenetics and any molecular testing, plus the bone marrow report that established the diagnosis. If the subtype is unclear or the reports are incomplete, a records-based pathology or hematology review may help clarify what is known and what is missing before anyone books travel.
Be careful about what a review can and cannot do. A review of existing documents can comment on the recorded diagnosis and flag gaps. It cannot examine the patient, cannot confirm fitness for intensive treatment, and cannot promise that a Chinese hospital will accept the case or offer a particular therapy. Those decisions belong to the treating hematology team after they see the patient and the full record.
Which treatment phase is the patient actually in?
Acute leukemia care is staged over time: induction to achieve remission, consolidation to deepen it, and for some patients allogeneic stem cell transplant. Each phase raises a different question about travelling.
If the patient has not started treatment, the question is whether starting in China is appropriate at all, and whether the delay involved in arranging it is safe. If the patient is mid-induction or awaiting count recovery, travel is usually a clinical question for the treating team first, because infection risk and blood-count recovery matter more than itinerary. If the patient is in remission and considering consolidation or transplant, the question becomes whether the receiving centre can continue the same protocol or a justified alternative, and how the transition is timed.
Ask the current hematologist a direct question: "Is there a window in which travel would not compromise this patient's treatment?" The answer depends on the individual case. No article, and no coordinator, can set that window.
Fitness to travel is a clinical decision
Long-haul travel with acute leukemia carries real risks: infection during travel, bleeding related to low platelets, fatigue, and the possibility of rapid deterioration away from the treating team. Air travel and airport transit also involve practical questions about medical clearance and assistance, which the airline and the treating clinicians must address for the individual patient.
The useful preparation is to ask the treating team what they would want to know before agreeing that travel is reasonable, and to ask what should happen if the patient becomes unwell en route. Do not treat a booked flight as evidence that travel is safe. If the patient has fever, active bleeding, worsening breathlessness or other acute symptoms, local urgent assessment takes priority over any overseas plan.
Travel insurance and medical evacuation arrangements are worth discussing early, because standard policies may not cover planned treatment abroad or may exclude pre-existing conditions. Confirm the terms with the insurer rather than assuming coverage.
Records that let a new team act, not just read
A receiving hematology team needs documents it can act on. In practice that means the diagnostic bone marrow reports, immunophenotyping, cytogenetics and molecular results; the treatment history with drug names, doses, cycles and responses; blood counts and chemistry over time; imaging; microbiology results for any infections; transfusion history; and a current medication list including anti-infectives and supportive drugs.
Ask the current team for a short clinical summary letter in English that states the diagnosis, the treatment given so far, the response, current problems and what they consider the next step. That letter is often more useful than a large unstructured file.
Then ask the receiving hospital what it requires and in what form, including whether translated or certified copies are needed and whether original slides or blocks should be sent for pathology review. These are provider-specific requirements; confirm them rather than assuming a standard.
What the receiving hospital must confirm in writing
Before committing to travel, get clear answers in writing about the clinical plan and its scope. Ask whether the hospital has reviewed the records and whether it is prepared to accept the patient for assessment, and be precise that acceptance for assessment is not the same as a confirmed treatment plan. A hospital can agree to see a patient and still conclude, after examination and its own testing, that a different approach is appropriate or that it cannot offer the treatment the family hoped for. Knowing that in advance changes how you plan the trip, the length of stay and the money you commit.
Ask which treatment approach the team would consider and why, and ask them to name the alternatives they would weigh for this specific subtype and phase. For AML, that conversation may involve the intensity of induction, the role of targeted agents in subtypes with an identifiable molecular target, and whether transplant is on the table. For ALL, it may involve Philadelphia-chromosome status, the place of tyrosine kinase inhibitors, and the same transplant question. You are not asking the hospital to commit to a protocol before it has seen the patient; you are asking whether its reasoning matches what your current team has explained, and where it differs.
Availability is a separate question from intent. Ask whether the diagnostics the plan depends on can be done at that hospital, including the immunophenotyping, cytogenetics and molecular testing that guide subtype-specific treatment, and whether supportive care such as blood product support, anti-infective treatment and intensive care is available on site. A centre that can treat leukemia but refers out its intensive care, or that sends molecular testing to another laboratory, will have different timing and different risks during a low blood count.
Then ask what the written plan and fee quote include. Do not assume that a quoted figure covers medicines, blood products, intensive care, isolation rooms, complications or a prolonged stay when counts recover slowly. Ask the named hospital what its quote covers and what is billed separately, and ask for that in writing rather than in a phone conversation. If the answer is vague, treat the figure as incomplete rather than as a ceiling.
For patients considering allogeneic transplant, be explicit that a hematology review does not establish transplant eligibility or the availability of a donor or slot. Those are separate clinical and institutional determinations, made after the transplant team assesses disease status, organ function, comorbidity and donor options. Ask separately whether the hospital's transplant programme would assess the patient, and what its own assessment process involves.
Timing deserves its own written answer. Ask how quickly the hospital could begin assessment after arrival, what it would need before that, and what happens to the plan if the patient arrives with a fever or a falling count. Acute leukemia does not wait for an itinerary, and a plan that assumes a stable patient at arrival is not a plan for this disease.
Continuity, language and the next step
Acute leukemia care is continuous. The handover question is who is responsible for the patient at each stage: the current team until departure, the receiving team from acceptance, and what happens if the plan changes. Ask both teams to agree the handover in writing, including which records were sent and which were received.
Language matters in a fast-moving illness. Ask whether the treating team can discuss the plan in English, whether interpretation is available for consent discussions, and who will explain results. Consent for intensive treatment should be understood, not just signed.
Our team can check the available diagnosis and records, identify missing information and suggest a relevant next step; this initial enquiry is free and is not a diagnosis or a promise of acceptance. You can begin with a brief summary through the enquiry form, email or WhatsApp, and share fuller records only after first contact. The hospital, not the coordinator, decides suitability.
Sources & scope of this guide
References and official service information relevant to this guide.
- hematology
- Related treatment reference
- Acute Myeloid Leukemia Treatment - NCI
- Acute Lymphoblastic Leukemia Treatment - NCI
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
